Time filter

Source Type

Song L.,BioChain Beijing Science and Technology Inc. | Li Y.,The Chinese PLA 309 Hospital
Advances in Clinical Chemistry | Year: 2015

SEPT9 gene methylation has been implicated as a biomarker for colorectal cancer (CRC) for more than 10. years and has been used clinically for more than 6. years. Studies have proven it to be an accurate, reliable, fast, and convenient method for CRC. In this chapter, we will first provide the background on the role of septin9 protein and the theoretical basis of the SEPT9 gene methylation assay. We will then focus on the performance of SEPT9 gene methylation assay for CRC early detection and screening by analyzing the data obtained in clinical trials and comparing its performance with other methods or markers. Finally, we will discuss the future applications of the assay in monitoring cancer recurrence, evaluating surgery, chemotherapy, and predicting long-term survival. We hope this chapter can provide a full overview of the theoretical basis, development, validation, and clinical applications of the SEPT9 assay for both basic science researchers and clinical practitioners. © 2015 Elsevier Inc. Source

Song L.,The Chinese PLA 309 Hospital | Song L.,BioChain Beijing Science and Technology Inc. | Yu H.,The Chinese PLA 309 Hospital | Li Y.,The Chinese PLA 309 Hospital
Molecular Diagnosis and Therapy | Year: 2015

Lung cancer is the most prevalent cancer in the world. Few effective and cheap methods are available so far for early detection and screening of lung cancer. Although histological and cytological examinations are gold standards in lung cancer diagnosis, patients are always at late stages when diagnosis is confirmed. Therefore, new diagnostic methods are needed urgently to increase the early diagnostic rate, enhance the confirmed diagnostic rate, and reduce mortality. The SHOX2 gene methylation assay has become a promising option for the above purposes. It has been shown to enhance the confirmed diagnostic rate of lung cancer in several clinical trials when combined with histological or cytological assays, and has the potential to become an early diagnostic tool. This article reviews the outcome of clinical trials using the SHOX2 gene methylation assay alone or in combination with other examinations, and suggests its future applications and research directions. © 2015, Springer International Publishing Switzerland. Source

Discover hidden collaborations